Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment.
Journal
Nature reviews. Gastroenterology & hepatology
ISSN: 1759-5053
Titre abrégé: Nat Rev Gastroenterol Hepatol
Pays: England
ID NLM: 101500079
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
accepted:
13
05
2022
pubmed:
23
6
2022
medline:
1
11
2022
entrez:
22
6
2022
Statut:
ppublish
Résumé
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic, relapsing immune-mediated disease with a varying and sometimes severe disease course. IBD is often diagnosed in early adulthood and can lead to a substantial decline in quality of life. It has been suggested that patients with IBD are at increased risk of depression and anxiety, but it is still unclear to what extent these diseases co-occur and in what sequence they arise. This Review summarizes the literature on the degree of co-occurrence of IBD with depression and anxiety and the temporal relationship between these diseases. We also discuss the effect of psychological stress on the onset and course of IBD. In addition, we outline the possible mechanisms underlying the co-occurrence of IBD and depression and anxiety, which include changes in brain signalling and morphology, increases in peripheral and intracerebral pro-inflammatory cytokines, impairment of the nitric oxide pathway, changes in vagal nerve signalling, gut dysbiosis and genetics. Finally, we examine the possible effects of treatment of depression and anxiety on the risk and course of IBD, the influence of psychological interventions on IBD, and the effects of IBD treatment on psychiatric comorbidity.
Identifiants
pubmed: 35732730
doi: 10.1038/s41575-022-00634-6
pii: 10.1038/s41575-022-00634-6
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
717-726Informations de copyright
© 2022. Springer Nature Limited.
Références
Podolsky, D. Inflammatory bowel disease. N. Engl. J. Med. 347, 417–429 (2002).
pubmed: 12167685
doi: 10.1056/NEJMra020831
Baumgart, D. C. & Sandborn, W. J. Crohn’s disease. Lancet 380, 1590–1605 (2013).
doi: 10.1016/S0140-6736(12)60026-9
Danese, S. & Fiocchi, C. Ulcerative colitis. N. Engl. J. Med. 365, 1713–1725 (2011).
pubmed: 22047562
doi: 10.1056/NEJMra1102942
Wehkamp, J., Götz, M., Herrlinger, K., Steurer, W. & Stange, E. F. Inflammatory bowel disease. Dtsch. Arztebl Int. 113, 72–82 (2016).
pubmed: 26900160
pmcid: 4782273
Walker, J. R. et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am. J. Gastroenterol. 103, 1989–1997 (2008).
pubmed: 18796096
doi: 10.1111/j.1572-0241.2008.01980.x
Panara, A. J. et al. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Aliment. Pharmacol. Ther. 39, 802–810 (2014).
pubmed: 24588323
doi: 10.1111/apt.12669
Persoons, P. et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Aliment. Pharmacol. Ther. 22, 101–110 (2005).
pubmed: 16011668
doi: 10.1111/j.1365-2036.2005.02535.x
Nowakowski, J., Chrobak, A. & Dudek, D. Psychiatric illnesses in inflammatory bowel diseases–psychiatric comorbidity and biological underpinnings. Psychiatr. Pol. 50, 1157–1166 (2016).
pubmed: 28211554
doi: 10.12740/PP/62382
Marrie, R. A., Graff, L. A., Fisk, J. D. & Patten, S. B. The relationship between symptoms of depression and anxiety and disease activity in IBD over time. Inflamm. Bowel Dis. 27, 1285–1293 (2021).
pubmed: 33393632
pmcid: 8314114
doi: 10.1093/ibd/izaa349
Morais, L. H., Schreiber, H. L. & Mazmanian, S. K. The gut microbiota–brain axis in behaviour and brain disorders. Nat. Rev. Microbiol. 19, 241–255 (2021).
pubmed: 33093662
doi: 10.1038/s41579-020-00460-0
Mikocka-Walus, A., Knowles, S. R., Keefer, L. & Graff, L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm. Bowel Dis. 22, 752–762 (2016).
pubmed: 26841224
doi: 10.1097/MIB.0000000000000620
Neuendorf, R., Harding, A., Stello, N., Hanes, D. & Wahbeh, H. Depression and anxiety in patients with inflammatory bowel disease: a systematic review. J. Psychosom. Res. 87, 70–80 (2016).
pubmed: 27411754
doi: 10.1016/j.jpsychores.2016.06.001
Barberio, B., Zamani, M., Black, C. J., Savarino, E. V. & Ford, A. C. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 6, 359–370 (2021).
pubmed: 33721557
doi: 10.1016/S2468-1253(21)00014-5
Stapersma, L., van den Brink, G., Szigethy, E. M., Escher, J. C. & Utens, E. M. W. J. Systematic review with meta-analysis: anxiety and depression in children and adolescents with inflammatory bowel disease. Aliment. Pharmacol. Ther. 48, 496–506 (2018).
pubmed: 29984495
doi: 10.1111/apt.14865
Frolkis, A. D. et al. Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. Gut 68, 1606–1612 (2019).
pubmed: 30337374
doi: 10.1136/gutjnl-2018-317182
Ananthakrishnan, A. N. et al. Association between depressive symptoms and incidence of Crohn’s disease and ulcerative colitis: results from the Nurses’ Health Study. Clin. Gastroenterol. Hepatol. 11, 57–62 (2013).
pubmed: 22944733
doi: 10.1016/j.cgh.2012.08.032
Blackwell, J. et al. Depression in individuals who subsequently develop inflammatory bowel disease: a population-based nested case-control study. Gut 70, 1642–1648 (2020).
pubmed: 33109601
doi: 10.1136/gutjnl-2020-322308
Bernstein, C. N. et al. Increased burden of psychiatric disorders in inflammatory bowel disease. Inflamm. Bowel Dis. 25, 360–368 (2019).
pubmed: 29986021
doi: 10.1093/ibd/izy235
Choi, K. et al. Risk of anxiety and depression in patients with inflammatory bowel disease: a nationwide, population-based study. J. Clin. Med. 8, 654 (2019).
pmcid: 6572298
doi: 10.3390/jcm8050654
Ludvigsson, J. F. et al. Association between inflammatory bowel disease and psychiatric morbidity and suicide: a Swedish nationwide population-based cohort study with sibling comparison. J. Crohn’s Colitis 15, 1824–1836 (2021).
doi: 10.1093/ecco-jcc/jjab039
Butwicka, A. et al. Association of childhood-onset inflammatory bowel disease with risk of psychiatric disorders and suicide attempt. JAMA Pediatr. 173, 969–978 (2019).
pubmed: 31424531
pmcid: 6704748
doi: 10.1001/jamapediatrics.2019.2662
Marrie, R. A. et al. Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiol. Psychiatr. Sci. 28, 333–342 (2019).
pubmed: 29098977
doi: 10.1017/S2045796017000579
Marrie, R. A. et al. Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. J. Psychosom. Res. 101, 17–23 (2017).
pubmed: 28867419
doi: 10.1016/j.jpsychores.2017.07.015
Fairbrass, K. M. et al. Bidirectional brain–gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. Gut https://doi.org/10.1136/gutjnl-2021-325985 (2021).
Alexakis, C., Kumar, S., Saxena, S. & Pollok, R. Systematic review with meta-analysis: the impact of a depressive state on disease course in adult inflammatory bowel disease. Aliment. Pharmacol. Ther. 46, 225–235 (2017).
pubmed: 28573652
doi: 10.1111/apt.14171
Duffy, L. C. et al. Relevance of major stress events as an indicator of disease activity prevalence in inflammatory bowel disease. Behav. Med. 17, 101–110 (1991).
pubmed: 1932843
doi: 10.1080/08964289.1991.9937553
Levenstein, S. et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am. J. Gastroenterol. 95, 1213–1220 (2000).
pubmed: 10811330
doi: 10.1111/j.1572-0241.2000.02012.x
Melinder, C., Hiyoshi, A., Fall, K., Halfvarson, J. & Montgomery, S. Stress resilience and the risk of inflammatory bowel disease: a cohort study of men living in Sweden. BMJ Open 7, e014315 (2017).
pubmed: 28130207
pmcid: 5278277
doi: 10.1136/bmjopen-2016-014315
Levenstein, S. et al. Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study. Am. J. Gastroenterol. 89, 1219–1225 (1994).
pubmed: 8053438
Miyazawa, T. et al. Long-term course of inflammatory bowel disease after the great east Japan earthquake. J. Gastroenterol. Hepatol. 33, 1956–1960 (2018).
pubmed: 29791048
doi: 10.1111/jgh.14286
Li, J., Nørgard, B., Precht, D. H. & Olsen, J. Psychological stress and inflammatory bowel disease: a follow-up study in parents who lost a child in Denmark. Am. J. Gastroenterol. 99, 1129–1133 (2004).
pubmed: 15180736
doi: 10.1111/j.1572-0241.2004.04155.x
Lerebours, E. et al. Stressful life events as a risk factor for inflammatory bowel disease onset: a population-based case–control study. Am. J. Gastroenterol. 102, 122–131 (2007).
pubmed: 17100973
doi: 10.1111/j.1572-0241.2006.00931.x
Targownik, L. E. et al. The relationship among perceived stress, symptoms, and inflammation in persons with inflammatory bowel disease. Am. J. Gastroenterol. 110, 1001–1012 (2015).
pubmed: 26077178
doi: 10.1038/ajg.2015.147
Bitton, A. et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am. J. Gastroenterol. 98, 2203–2208 (2003).
pubmed: 14572569
doi: 10.1111/j.1572-0241.2003.07717.x
Jaghult, S. et al. Stress as a trigger for relapses in IBD: a case-crossover study. Gastroenterol. Res. 6, 10–16 (2013).
Cruz-Pereira, J. S. et al. Depression’s unholy trinity: dysregulated stress, immunity, and the microbiome. Annu. Rev. Physiol. 71, 49–78 (2020).
Galea, I., Bechmann, I. & Perry, V. H. What is immune privilege (not)? Trends Immunol. 28, 12–18 (2007).
pubmed: 17129764
doi: 10.1016/j.it.2006.11.004
Thomson, C. A., McColl, A., Cavanagh, J. & Graham, G. J. Peripheral inflammation is associated with remote global gene expression changes in the brain. J. Neuroinflammation 11, 73 (2014).
pubmed: 24708794
pmcid: 4022192
doi: 10.1186/1742-2094-11-73
Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46–56 (2008).
pubmed: 18073775
pmcid: 2919277
doi: 10.1038/nrn2297
D’Mello, C. & Swain, M. G. Immune-to-brain communication pathways in inflammation-associated sickness and depression. Curr. Top. Behav. Neurosci. https://doi.org/10.1007/7854_2016_37 (2016).
doi: 10.1007/7854_2016_37
Carloni, S. et al. Identification of a choroid plexus vascular barrier closing during intestinal inflammation. Science 22, 439–448 (2021).
doi: 10.1126/science.abc6108
Haj-Mirzaian, A. et al. Anxiety- and depressive-like behaviors are associated with altered hippocampal energy and inflammatory status in a mouse model of Crohn’s disease. Neuroscience 366, 124–137 (2017).
pubmed: 29080717
doi: 10.1016/j.neuroscience.2017.10.023
Heydarpour, P. et al. Behavioral despair associated with a mouse model of Crohn’s disease: role of nitric oxide pathway. Prog. Neuropsychopharmacol. Biol. Psychiatry 64, 131–141 (2016).
pubmed: 26268932
doi: 10.1016/j.pnpbp.2015.08.004
Zonis, S. et al. Chronic intestinal inflammation alters hippocampal neurogenesis. J. Neuroinflammation 12, 65 (2015).
pubmed: 25889852
pmcid: 4403851
doi: 10.1186/s12974-015-0281-0
Kraus, M. R., Schäfer, A., Faller, H., Csef, H. & Scheurlen, M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J. Clin. Psychiatry 64, 708–714 (2003).
pubmed: 12823087
doi: 10.4088/JCP.v64n0614
Ghia, J.-E., Blennerhassett, P. & Collins, S. M. Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression. J. Clin. Invest. 118, 2209–2218 (2008).
pubmed: 18451995
pmcid: 2350428
Zhang, L., Hu, L., Chen, M. & Yu, B. Exogenous interleukin-6 facilitated the contraction of the colon in a depression rat model. Dig. Dis. Sci. 58, 2187–2196 (2013).
pubmed: 23589140
doi: 10.1007/s10620-013-2656-3
Ghia, J.-E. et al. Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology 136, 2280–2288 (2009).
pubmed: 19272381
doi: 10.1053/j.gastro.2009.02.069
Ghia, J.-E., Park, A. J., Blennerhassett, P., Khan, W. I. & Collins, S. M. Adoptive transfer of macrophage from mice with depression-like behavior enhances susceptibility to colitis. Inflamm. Bowel Dis. 17, 1474–1489 (2011).
pubmed: 21246669
doi: 10.1002/ibd.21531
Meregnani, J. et al. Anti-inflammatory effect of vagus nerve stimulation in a rat model of inflammatory bowel disease. Auton. Neurosci. Basic. Clin. 160, 82–89 (2011).
doi: 10.1016/j.autneu.2010.10.007
Bonaz, B. L. & Bernstein, C. N. Brain-gut interactions in inflammatory bowel disease. Gastroenterology 144, 36–49 (2013).
pubmed: 23063970
doi: 10.1053/j.gastro.2012.10.003
Emge, J. R. et al. Modulation of the microbiota-gut-brain axis by probiotics in a murine model of inflammatory bowel disease. Am. J. Physiol. Liver Physiol. 310, G989–G998 (2016).
Gao, X. et al. Chronic stress promotes colitis by disturbing the gut microbiota and triggering immune system response. Proc. Natl Acad. Sci. USA 115, E2960–E2969 (2018).
pubmed: 29531080
pmcid: 5879702
doi: 10.1073/pnas.1720696115
Li, N. et al. Fecal microbiota transplantation from chronic unpredictable mild stress mice donors affects anxiety-like and depression-like behavior in recipient mice via the gut microbiota-inflammation-brain axis. Stress 22, 592–602 (2019).
pubmed: 31124390
doi: 10.1080/10253890.2019.1617267
Marcondes Ávila, P. R. et al. Effects of microbiota transplantation and the role of the vagus nerve in gut–brain axis in animals subjected to chronic mild stress. J. Affect. Disord. 277, 410–416 (2020).
pubmed: 32866799
doi: 10.1016/j.jad.2020.08.013
Agostini, A. et al. Brain functional changes in patients with ulcerative colitis: a functional magnetic resonance imaging study on emotional processing. Inflamm. Bowel Dis. 17, 1769–1777 (2011).
pubmed: 21744432
doi: 10.1002/ibd.21549
Agostini, A. et al. New insights into the brain involvement in patients with Crohn’s disease: a voxel-based morphometry study. Neurogastroenterol. Motil. 25, 147–154 (2013).
pubmed: 22998431
doi: 10.1111/nmo.12017
Vogt, B. A. Pain and emotion interactions in subregions of the cingulate gyrus. Nat. Rev. Neurosci. 6, 533–544 (2009).
doi: 10.1038/nrn1704
Nair, V. A. et al. Structural imaging changes and behavioral correlates in patients with Crohn’s disease in remission. Front. Hum. Neurosci. 10, 460 (2016).
pubmed: 27695405
pmcid: 5025433
doi: 10.3389/fnhum.2016.00460
Manichanh, C., Borruel, N., Casellas, F. & Guarner, F. The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 9, 599–608 (2012).
pubmed: 22907164
doi: 10.1038/nrgastro.2012.152
Schirmer, M., Garner, A., Vlamakis, H. & Xavier, R. J. Microbial genes and pathways in inflammatory bowel disease. Nat. Rev. Microbiol. 17, 497–511 (2019).
pubmed: 31249397
pmcid: 6759048
doi: 10.1038/s41579-019-0213-6
Limbana, T., Khan, F. & Eskander, N. Gut microbiome and depression: how microbes affect the way we think. Cureus 12, e9966 (2020).
pubmed: 32983670
pmcid: 7510518
Winter, G., Hart, R. A., Charlesworth, R. P. G. & Sharpley, C. F. Gut microbiome and depression: what we know and what we need to know. Rev. Neurosci. 29, 629–643 (2018).
pubmed: 29397391
doi: 10.1515/revneuro-2017-0072
Jiang, H. et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav. Immun. 48, 186–194 (2015).
pubmed: 25882912
doi: 10.1016/j.bbi.2015.03.016
Kilinçarslan, S. & Evrensel, A. The effect of fecal microbiota transplantation on psychiatric symptoms among patients with inflammatory bowel disease: an experimental study. Actas Esp. Psiquiatr. 48, 1–7 (2020).
pubmed: 32297646
Sullivan, P. F., Daly, M. J. & O’Donovan, M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat. Rev. Genet. 13, 537–551 (2014).
doi: 10.1038/nrg3240
Daly, J. et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol. Psychiatry 18, 497–511 (2013).
pubmed: 22472876
doi: 10.1038/mp.2012.21
Kevans, D. et al. IBD genetic risk profile in healthy first-degree relatives of Crohn’s disease patients. J. Crohns. Colitis 10, 209–215 (2016).
pubmed: 26512135
doi: 10.1093/ecco-jcc/jjv197
International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia that overlaps with bipolar disorder. Nature 460, 748–752 (2009).
pmcid: 3912837
doi: 10.1038/nature08185
Luo, J. et al. Depression and inflammatory bowel disease: a bidirectional two-sample mendelian randomization study. J. Crohns Colitis 16, 633–642 (2022).
pubmed: 34739073
doi: 10.1093/ecco-jcc/jjab191
De Lange, K. M. et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49, 256–261 (2017).
pubmed: 28067908
pmcid: 5289481
doi: 10.1038/ng.3760
Frenkel, S. et al. Copy number variation-based gene set analysis reveals cytokine signalling pathways associated with psychiatric comorbidity in patients with inflammatory bowel disease. Genomics 112, 683–693 (2020).
pubmed: 31075388
doi: 10.1016/j.ygeno.2019.05.001
Janssen, D. G. A., Caniato, R. N., Verster, J. C. & Baune, B. T. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum. Psychopharmacol. 25, 201–215 (2010).
pubmed: 20373471
doi: 10.1002/hup.1103
Minaiyan, M., Hajhashemi, V., Rabbani, M., Fattahian, E. & Mahzouni, P. Evaluation of anti-colitic effect of fluvoxamine against acetic acid-induced colitis in normal and reserpinized depressed rats. Eur. J. Pharmacol. 746, 293–300 (2015).
pubmed: 25460023
doi: 10.1016/j.ejphar.2014.11.016
Minaiyan, M., Hajhashemi, V., Rabbani, M., Fattahian, E. & Mahzouni, P. Effect of venlafaxine on experimental colitis in normal and reserpinised depressed rats. Res. Pharm. Sci. 10, 295–306 (2015).
pubmed: 26600857
pmcid: 4623619
Fattahian, E., Hajhashemi, V., Rabbani, M., Minaiyan, M. & Mahzouni, P. Anti-inflammatory effect of amitriptyline on ulcerative colitis in normal and reserpine-induced depressed rats. Iran. J. Pharm. Res. 15, 125–137 (2016).
pubmed: 28228811
pmcid: 5242359
Zabihi, M., Hajhashemi, V., Minaiyan, M. & Talebi, A. Evaluation of the central and peripheral effects of doxepin on carrageenan-induced inflammatory paw edema in rat. Res. Pharm. Sci. 12, 337–345 (2017).
pubmed: 28855946
pmcid: 5566009
doi: 10.4103/1735-5362.212052
Mikocka-Walus, A. et al. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database Syst. Rev. 4, CD012680 (2019).
pubmed: 30977111
Mikocka-Walus, A., Ford, A. C. & Drossman, D. A. Antidepressants in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 17, 184–192 (2020).
pubmed: 32071420
doi: 10.1038/s41575-019-0259-y
Goodhand, J. R. et al. Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. Inflamm. Bowel Dis. 18, 1232–1239 (2012).
pubmed: 22234954
doi: 10.1002/ibd.21846
Daghaghzadeh, H. et al. Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: a double-blind controlled study. J. Res. Med. Sci. 20, 595 (2015).
pubmed: 26600836
pmcid: 4621655
doi: 10.4103/1735-1995.165969
Iskandar, H. N. et al. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J. Clin. Gastroenterol. 48, 423–429 (2014).
pubmed: 24406434
pmcid: 4111227
doi: 10.1097/MCG.0000000000000049
Hall, B. J., Hamlin, P. J., Gracie, D. J. & Ford, A. C. The effect of antidepressants on the course of inflammatory bowel disease. Can. J. Gastroenterol. Hepatol. 2018, 2047242 (2018).
pubmed: 30271765
pmcid: 6151237
doi: 10.1155/2018/2047242
Mikocka-Walus, A. et al. Fluoxetine for maintenance of remission and to improve quality of life in patients with Crohn’s disease: a pilot randomized placebo-controlled trial. J. Crohns Colitis 11, 509–514 (2017).
pubmed: 27664274
Keefer, L. Behavioural medicine and gastrointestinal disorders: the promise of positive psychology. Nat. Rev. Gastroenterol. Hepatol. 15, 378–386 (2018).
pubmed: 29651112
doi: 10.1038/s41575-018-0001-1
Timmer, A. et al. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.cd006913.pub2 (2011).
doi: 10.1002/14651858.cd006913.pub2
pubmed: 21491415
pmcid: 7150228
Gracie, D. J. et al. Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2, 189–199 (2017).
pubmed: 28404134
doi: 10.1016/S2468-1253(16)30206-0
Lores, T. et al. Integrated psychological care reduces health care costs at a hospital-based inflammatory bowel disease service. Clin. Gastroenterol. Hepatol. 19, 96–103 (2021).
pubmed: 32007538
doi: 10.1016/j.cgh.2020.01.030
Horst, S. et al. Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease. Dig. Dis. Sci. 60, 465–470 (2015).
pubmed: 25274158
doi: 10.1007/s10620-014-3375-0
Zhang, M. et al. Improvement of psychological status after infliximab treatment in patients with newly diagnosed Crohn’s disease. Patient Prefer. Adherence 12, 879–885 (2018).
pubmed: 29872273
pmcid: 5973631
doi: 10.2147/PPA.S156883
Stevens, B. W. et al. Vedolizumab therapy is associated with an improvement in sleep quality and mood in inflammatory bowel diseases. Dig. Dis. Sci. 62, 197–206 (2017).
pubmed: 27796768
doi: 10.1007/s10620-016-4356-2
Raison, C. L. et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. Arch. Gen. Psychiatry 70, 31–41 (2013).
Clark, J. G. et al. Predictors of depression in youth with Crohn disease. J. Pediatr. Gastroenterol. Nutr. 58, 569–573 (2014).
pubmed: 24343281
pmcid: 4096803
doi: 10.1097/MPG.0000000000000277
Thillard, E.-M. et al. Psychiatric adverse events associated with infliximab: a cohort study from the French nationwide discharge abstract database. Front. Pharmacol. 11, 513 (2020).
pubmed: 32390850
pmcid: 7188945
doi: 10.3389/fphar.2020.00513